Interleukin-18 promoter polymorphism in patients with rheumatoid arthritis

被引:39
作者
Pawlik, A
Kurzawski, M
Czerny, B
Gawronska-Szklarz, B
Drozdzik, M
Herczynska, M
机构
[1] Pomeranian Med Univ, Dept Pharmacokinet & Therapeut Drug Monitoring, PL-70111 Szczecin, Poland
[2] Pomeranian Med Univ, Dept Clin & Expt Pharmacol, PL-70111 Szczecin, Poland
[3] Cty Hosp, Dept Rheumatol, Szczecin, Poland
来源
TISSUE ANTIGENS | 2006年 / 67卷 / 05期
关键词
interleukin-18; polymorphism; rheumatoid arthritis;
D O I
10.1111/j.1399-0039.2006.00582.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 [细胞生物学]; 090102 [作物遗传育种];
摘要
Rheumatoid arthritis (RA) is a chronic inflammatory disease in which interleukin (IL)-18 plays an important role. However, there are controversial reports on IL-18 promoter polymorphism as an independent marker of RA susceptibility. The aim of present study was to examine the IL-18 promoter polymorphism in patients with RA, and its association with disease susceptibility, activity and severity. We examined 309 patients with RA from a Polish population diagnosed according to the criteria of American College of Rheumatology. An allele-specific polymerase chain reaction was used for analysis of the polymorphisms in positions - 137 and - 607 in promoter region of IL-18 gene. A significantly decreased number of subjects with AC/AC and AG/AG diplotypes was observed among RA patients as compared with healthy controls (OR - 0.51, 95%CI 0.28-0.95, P = 0.045) and (OR - 0.12, 95% CI 0.02-0.97, P = 0.042), respectively. Nevertheless, there was no significant association with disease activity, joint erosions, extra-articular manifestations, rheumatoid factor. Above results suggest that IL-18-137 and - 607 promoter polymorphisms are not the significant factors influencing RA course and severity in a Polish population.
引用
收藏
页码:415 / 418
页数:4
相关论文
共 14 条
[1]
THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY PRELIMINARY CORE SET OF DISEASE-ACTIVITY MEASURES FOR RHEUMATOID-ARTHRITIS CLINICAL-TRIALS [J].
FELSON, DT ;
ANDERSON, JJ ;
BOERS, M ;
BOMBARDIER, C ;
CHERNOFF, M ;
FRIED, B ;
FURST, D ;
GOLDSMITH, C ;
KIESZAK, S ;
LIGHTFOOT, R ;
PAULUS, H ;
TUGWELL, P ;
WEINBLATT, M ;
WIDMARK, R ;
WILLIAMS, HJ ;
WOLFE, F .
ARTHRITIS AND RHEUMATISM, 1993, 36 (06) :729-740
[2]
Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation [J].
Giedraitis, V ;
He, B ;
Huang, WX ;
Hillert, J .
JOURNAL OF NEUROIMMUNOLOGY, 2001, 112 (1-2) :146-152
[3]
Disease association of two distinct interleukin-18 promoter polymorphisms in Caucasian rheumatoid arthritis patients [J].
Gracie, JA ;
Koyama, N ;
Murdoch, J ;
Field, M ;
McGarry, F ;
Crilly, A ;
Schobel, A ;
Madhok, R ;
Pons-Kühnemann, J ;
McInnes, IB ;
Möller, B .
GENES AND IMMUNITY, 2005, 6 (03) :211-216
[4]
A proinflammatory role for IL-18 in rheumatoid arthritis [J].
Gracie, JA ;
Forsey, RJ ;
Chan, WL ;
Gilmour, A ;
Leung, BP ;
Greer, MR ;
Kennedy, K ;
Carter, R ;
Wei, XQ ;
Xu, DM ;
Field, M ;
Foulis, A ;
Liew, FY ;
McInnes, IB .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (10) :1393-1401
[5]
GUSTINCICH S, 1991, BIOTECHNIQUES, V11, P298
[6]
Genetic epidemiology of rheumatoid arthritis [J].
Harney, S ;
Wordsworth, BP .
TISSUE ANTIGENS, 2002, 60 (06) :465-473
[7]
Linkage of cytokine genes to rheumatoid arthritis. Evidence of genetic heterogeneity [J].
John, S ;
Myerscough, A ;
Marlow, A ;
Hajeer, A ;
Silman, A ;
Ollier, W ;
Worthington, J .
ANNALS OF THE RHEUMATIC DISEASES, 1998, 57 (06) :361-365
[8]
Interleukin-18 promoter Polymorphisms in type 1 diabetes [J].
Kretowski, A ;
Mironczuk, K ;
Karpinska, A ;
Bojaryn, U ;
Kinalski, M ;
Puchalski, Z ;
Kinalska, I .
DIABETES, 2002, 51 (11) :3347-3349
[9]
Pathophysiological roles for IL-18 in inflammatory arthritis [J].
Matsui, K ;
Tsutsui, H ;
Nakanishi, K .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2003, 7 (06) :701-724
[10]
Interleukin 18: a pleiotropic participant in chronic inflammation [J].
McInnes, IB ;
Gracie, JA ;
Leung, BP ;
Wei, XQ ;
Liew, FY .
IMMUNOLOGY TODAY, 2000, 21 (07) :312-315